EA202092296A1 - MOLECULAR ADJUVANT - Google Patents
MOLECULAR ADJUVANTInfo
- Publication number
- EA202092296A1 EA202092296A1 EA202092296A EA202092296A EA202092296A1 EA 202092296 A1 EA202092296 A1 EA 202092296A1 EA 202092296 A EA202092296 A EA 202092296A EA 202092296 A EA202092296 A EA 202092296A EA 202092296 A1 EA202092296 A1 EA 202092296A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- daa
- adc
- disease characterized
- molecular adjuvant
- Prior art date
Links
Abstract
Данное изобретение относится к видам терапии для лечения заболевания, характеризующегося ассоциированным с заболеванием антигеном (DAA); описаны способы вакцинации. В частности, в описании раскрыты молекулярные адъюванты ADC против CD25 для применения в индукции или усилении иммунного ответа субъекта против DAA, что позволяет лечить заболевание, характеризующееся DAA. Также описаны схемы применения для лечения солидных опухолей с помощью ADC. Данное описание относится к лечению патологических состояний, например злокачественное новообразование, с помощью ADC против CD25.This invention relates to therapies for the treatment of a disease characterized by a disease associated antigen (DAA); methods of vaccination are described. In particular, the disclosure discloses molecular adjuvants of anti-CD25 ADC for use in inducing or enhancing a subject's immune response against DAA, which allows the treatment of a disease characterized by DAA. Regimens for the treatment of solid tumors with ADC are also described. This disclosure relates to the treatment of pathological conditions such as cancer with anti-CD25 ADCs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1818152.9A GB201818152D0 (en) | 2018-11-07 | 2018-11-07 | Molecular adjuvant |
PCT/EP2019/063262 WO2019224275A1 (en) | 2018-05-23 | 2019-05-22 | Molecular adjuvant |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092296A1 true EA202092296A1 (en) | 2021-05-21 |
Family
ID=64655555
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092296A EA202092296A1 (en) | 2018-11-07 | 2019-05-22 | MOLECULAR ADJUVANT |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA202092296A1 (en) |
GB (1) | GB201818152D0 (en) |
-
2018
- 2018-11-07 GB GBGB1818152.9A patent/GB201818152D0/en not_active Ceased
-
2019
- 2019-05-22 EA EA202092296A patent/EA202092296A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
GB201818152D0 (en) | 2018-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500670A1 (en) | Molecular adjuvant | |
EA201890355A1 (en) | NEW METHODS OF IMMUNE RESPONSE INDUCTION | |
BR112021018694A2 (en) | Extracellular vesicles for vaccine delivery | |
MX2022002504A (en) | Antibodies to cd40. | |
WO2016109546A3 (en) | Methods and compositions for prognosis and treatment of cancers | |
EA201000207A1 (en) | NEW IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY | |
MX2018010586A (en) | Sting activating nanovaccine for immunotherapy. | |
EA201800148A1 (en) | CHALLENGE VACCINE FOR CANCER TREATMENT | |
TW201613558A (en) | Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus | |
UY37594A (en) | IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY | |
EA201491171A1 (en) | SUBSTANCES CONTAINING IMPROVED IL-12 GENETIC STRUCTURES, VACCINES, IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF THEIR USE | |
PH12016502445A1 (en) | Antibodies directed against cd127 | |
EA201890747A1 (en) | METHODS OF TREATING INFLAMMATORY DISEASES | |
CY1123275T1 (en) | BINDING MOLECULES SPECIFICALLY FOR IL-21 AND USES THEREOF | |
EA201891601A1 (en) | METHODS AND COMPOSITIONS ENHANCED EFFICIENCY BY MEDIATED SUPERANTIGEN IMMUNOTHERAPY OF MALIGNANT TUMORS | |
EA201291373A1 (en) | VACCINE AND METHODS TO ELIMINATE INFECTION CAUSED BY CAMPYLOBACTER | |
EA202090401A1 (en) | ANTI-TIM-3 ANTIBODIES AND THEIR APPLICATION | |
MX2023001540A (en) | Cancer vaccines and methods of treatment using the same. | |
BRPI0920622A8 (en) | African equine disease virus vaccine | |
CY1122061T1 (en) | CHIMERIC SOLUBLE INTERLEUKIN-10 RECEPTOR AND THERAPEUTIC USE THEREOF | |
EA202092824A1 (en) | COMBINATION THERAPY | |
EA202092296A1 (en) | MOLECULAR ADJUVANT | |
MX2022000263A (en) | Novel cancer antigens and methods. | |
MX2021015765A (en) | Novel cancer antigens and methods. | |
MX2021004453A (en) | Novel cancer antigens and methods. |